Cargando…

Metabolic network analysis predicts efficacy of FDA-approved drugs targeting the causative agent of a neglected tropical disease

BACKGROUND: Systems biology holds promise as a new approach to drug target identification and drug discovery against neglected tropical diseases. Genome-scale metabolic reconstructions, assembled from annotated genomes and a vast array of bioinformatics/biochemical resources, provide a framework for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chavali, Arvind K, Blazier, Anna S, Tlaxca, Jose L, Jensen, Paul A, Pearson, Richard D, Papin, Jason A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388006/ https://www.ncbi.nlm.nih.gov/pubmed/22540944 http://dx.doi.org/10.1186/1752-0509-6-27

Ejemplares similares

Integration of expression data in genome-scale metabolic network reconstructions
por: Blazier, Anna S., et al.
Publicado: (2012)

Reconciling high-throughput gene essentiality data with metabolic network reconstructions
por: Blazier, Anna S., et al.
Publicado: (2019)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer
por: Li, Mei, et al.
Publicado: (2022)

A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents
por: Madrid, Peter B., et al.
Publicado: (2013)

New agents for the treatment of lymphoid leukemia and lymphoma: focus on recent FDA approvals
por: Stancu, Andreea Lucia, et al.
Publicado: (2014)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

First vaccine approval under the FDA Animal Rule
por: Beasley, David W C, et al.
Publicado: (2016)

Systems analysis of metabolism in the pathogenic trypanosomatid Leishmania major
por: Chavali, Arvind K, et al.
Publicado: (2008)

In silico Selection and Experimental Validation of FDA-Approved Drugs as Anti-quorum Sensing Agents
por: Mellini, Marta, et al.
Publicado: (2019)

Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval
por: Shaw, Daniel L., et al.
Publicado: (2018)

Molecular docking analysis of FDA approved drugs with the glycoprotein from Junin and Machupo viruses
por: Malhotra, Himani, et al.
Publicado: (2022)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA-approved medications that impair human spermatogenesis
por: Ding, Jiayi, et al.
Publicado: (2016)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

FDA approved vaccines for monkeypox: Current eminence
por: Chopra, Hitesh, et al.
Publicado: (2022)

Repurposing the FDA-Approved Pinworm Drug Pyrvinium as a Novel Chemotherapeutic Agent for Intestinal Polyposis
por: Li, Bin, et al.
Publicado: (2014)

Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
por: Nunes, Débora, et al.
Publicado: (2022)

Immunotherapy for Breast Cancer: First FDA Approved Regimen
por: Soare, Georgiana R., et al.
Publicado: (2019)

Impact of Nutrition or FDA-Approved Medicine Repurposing on Metabolic Syndrome and Diabetic Complications
por: Cai, Lu
Publicado: (2023)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

FDA-Approved Natural Polymers for Fast Dissolving Tablets
por: Alam, Md Tausif, et al.
Publicado: (2014)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

A Comprehensive Map of FDA-Approved Pharmaceutical Products
por: Zhong, Hao, et al.
Publicado: (2018)

THPdb: Database of FDA-approved peptide and protein therapeutics
por: Usmani, Salman Sadullah, et al.
Publicado: (2017)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
por: Gherghescu, Ioana, et al.
Publicado: (2020)

FDA efficiency for approval process of COVID-19 therapeutics
por: Cassidy, Christine, et al.
Publicado: (2020)

Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective
por: Drozda, Katarzyna, et al.
Publicado: (2018)

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
por: Tong, Juliana T. W., et al.
Publicado: (2021)

Prescribing of FDA-approved and compounded hormone therapy differs by specialty
por: Constantine, Ginger D., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dnkea0cfnja6uhkg34116bfpji